{"transactions":[{"id":673979,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":673978,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":673977,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":755321,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:39:26.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0002038311-26-000002","document":"form4-06022026_080621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000002/form4-06022026_080621.xml","form_type":"4"}},{"id":1194867,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-21T20:48:56.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant.  \"Date of Grant\" shall mean March 20, 2025."}],"balance_after":31000,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-008783","document":"form4-03212025_080352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000141588925008783/form4-03212025_080352.xml","form_type":"4"}},{"id":1402611,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-19T22:31:10.000Z","date":"2024-09-17","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. \"Date of Grant\" shall mean September 17, 2024."}],"balance_after":2000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001415889-24-023724","document":"form4-09192024_100906.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000141588924023724/form4-09192024_100906.xml","form_type":"4"}}]}